Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group.

Schnitzer TJ, Truitt K, Fleischmann R, Dalgin P, Block J, Zeng Q, Bolognese J, Seidenberg B, Ehrich EW.

Clin Ther. 1999 Oct;21(10):1688-702.

PMID:
10566565
2.
3.

Rofecoxib for rheumatoid arthritis.

Garner SE, Fidan DD, Frankish RR, Judd MG, Towheed TE, Wells G, Tugwell P.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003685. Review.

PMID:
15674912
4.

New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.

Hochberg MC.

Semin Arthritis Rheum. 2002 Dec;32(3 Suppl 1):4-14. Review.

PMID:
12528069
5.

Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.

Hawkey CJ, Jackson L, Harper SE, Simon TJ, Mortensen E, Lines CR.

Aliment Pharmacol Ther. 2001 Jan;15(1):1-9. Review.

6.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
7.

Rofecoxib.

Scott LJ, Lamb HM.

Drugs. 1999 Sep;58(3):499-505; discussion 506-7. Review.

PMID:
10493277
8.

[Pharma-clinics. The drug of the month. Rofecoxib (Vioxx)].

Scheen AJ.

Rev Med Liege. 2000 Jul;55(7):751-3. Review. French.

PMID:
11014111

Supplemental Content

Support Center